Results 61 to 70 of about 14,520 (202)

ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer [PDF]

, 2023
Fulvestrant is used to treat patients with hormone receptor positive advanced breast cancer but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant in patients with activating ESR1 ...
Toy, Weiyi, Herrera-Abreu, MT, Cutts, RJ, Toy, W, Sim, Li-Xuan, Cutts, Rosalind J., Macpherson, Iain R., Ring, A, Kilburn, Lucy S., Pearson, A, Pearson, Alex, Hou, Y, Ring, Alistair, Shah, H, Turner, Nicholas C., Bliss, Judith M., Chandarlapaty, S, Sim, L-X, Moretti, L, Katzenellenbogen, John A., Macpherson, IR, Moretti, Laura, Kilburn, LS, Bliss, JM, Kingston, Belinda, Herrera-Abreu, Maria Teresa, Turner, NC, Katzenellenbogen, JA, Johnson, H, Kingston, B, Chandarlapaty, Sarat, Shah, Heena, Johnson, Hannah, Hou, Yingwei   +33 more
core   +1 more source

Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 7, July 2026.
ABSTRACT Purpose Prevalence of breast cancer (BC) increases with age, but the external validity of data obtained from pivotal trials of medicinal products remains a concern due to the underrepresentation of frail and older adults. Cyclin‐dependent kinase inhibitors (CDKi), palbociclib, abemaciclib, and ribociclib are considered an essential part of the
Blair Rajamaki, Olli Tenhunen, Liisa Pylkkänen, Thuan Vo, Anne Paakinaho, Miia Turpeinen, Sirpa Hartikainen, Anna‐Maija Tolppanen   +7 more
wiley   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, Volume 13, Issue 33, 15 June 2026.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source

Combinatorial use of trastuzumab and fulvestrant (CalcuSyn).

, 2017
Combinatorial use of trastuzumab and fulvestrant (CalcuSyn).
Meixin Ge (3611657), Yijun Jia (608399), Fang Bai (1612534), Qing Lin (5273), Kejin Wu (608405), Ziyi Weng (608404), Qing Chen (131379), Yunshu Lu (608402), Longlong Ding (608403)   +8 more
core   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

Knockdown of MED1 sensitizes breast cancer cells to fulvestrant treatment.

, 2013
(A) BT474-tet-shMED1, ZR75-1-tet-shMED1 and MCF-7-tet-shMED1 cells were treated with vehicle (-Dox) or doxycycline (+Dox) and subjected to western blot analyses using indicated antibodies.
Yongquan Li (224436), Jiajun Cui (417692), Lijiang Zhang (439513), Kenneth Nephew (439515), Marissa Leonard (439514), Xiaoting Zhang (439516)   +5 more
core   +1 more source

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and Fulvestrant in HER2-Mutated Breast Cancer

, 2022
PURPOSE: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer. PATIENTS AND METHODS: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant in patients ...
Lin, Nancy U., Cobleigh, Melody, Pluard, Timothy J., Freedman, Rachel A., Haas, Brittney, Bose, Ron, Luo, Jingqin, Marcom, P. Kelly, Gao, Feng, Valdez-Albini, Frances, Lalani, Alshad S., Kimmick, Gretchen, Pegram, Mark D., Bucheit, Leslie, Carey, Lisa A., Nangia, Julie R., Winer, Eric P., Ma, Cynthia X., Lu, Janice, Jones, Jason M., Ellis, Matthew J., Goetz, Matthew P., Anderson, Jill, Bryce, Richard, Thomas, Shana   +24 more
core   +1 more source

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.

PLoS ONE, 2017
PurposeTo investigate the effects of trastuzumab (herceptin) and fulvestrant (falsodex) either in combination or alone, on downstream cell signaling pathways in lab-cultured human HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474, as well as on ...
Qing Chen, Ziyi Weng, Yunshu Lu, Yijun Jia, Longlong Ding, Fang Bai, Meixin Ge, Qing Lin, Kejin Wu   +8 more
doaj   +1 more source

Real‐World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Objective Metronomic chemotherapy (mCHT) is widely used in the treatment of breast cancer due to its low toxicity and convenience. However, there remain real‐world studies with satisfactory samples focusing on mCHT in advanced breast cancer. Methods Enrolled patients were assigned into capecitabine‐based (X‐based) group and other mCHT group ...
Hanxing Zhou, Linmin Chen, Qianyi Lu, Huailiang Wu, Kuikui Jiang, Fei Xu, Shusen Wang   +6 more
wiley   +1 more source

High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer

, 2016
Purpose: Resistance to endocrine therapy in estrogen receptor-positive (ER +) breast cancer remains a major clinical problem. Recently, the CDK4/6 inhibitor palbociclib combined with letrozole or fulvestrant was approved for treatment of ER + advanced ...
Ditzel, Henrik J, Elias, Daniel, Alves, Carla Maria Lourenco; id_orcid, Lyng, Maria B, Bak, Martin, Kirkegaard, Tove, Lykkesfeldt, Anne E   +6 more
core   +1 more source